Get the Weekly Intelligence Brief — top committee picks every Sunday.
NVS · NYSE · STOCK

Novartis (NVS) Stock Analysis

Healthcare Updated September 21, 2026
$140.37
52W $121.57 – $170.46
52/100
$266.80B
21.2
0.46
AI Committee Verdict
Watch
52/100
Conviction: Contested · 50% agreement · 6 analysts
+11.3%
-13.2%
0.86:1
Contested

Is NVS Bullish or Bearish?

Mixed. Innellis AI committee rates Novartis AG (NVS) Watch with a composite score of 52/100 , based on 6 analysts with 50% agreement. Last updated September 21, 2026.

What Would Change This View

Upgrade to Buy
Requires a committee score of 60.0 — +7.75 from today. Applies on the first day at or above the line; upgrades are never dampened.
Downgrade to Reduce
Requires the score to fall below 40.0 — -12.25 from today. The band boundary is 45.0, but a one-step downgrade must clear a further margin first. A score oscillating around the line should not change the rating every night.

Executive Summary

The committee is genuinely divided. Macro Analyst sees a compelling case. Risk Analyst remains cautious — bollinger bandwidth of 27.9% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.

Bull & Bear Case

Bull Case
  • ROE of 29.9% shows genuine earnings power backing the valuation — Value
  • Dividend yield of 3.7% pays you to wait — Value
  • Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
Bear Case
  • Price-to-book of 5.5x prices in significant intangible value — Value
  • EPS declining -3.5% YoY despite any revenue growth — Growth
  • MACD histogram negative -- bearish momentum — Technical
  • Bollinger bandwidth of 27.9% signals elevated volatility — Risk
Both cases are generated from quantitative data signals, not qualitative or forward-looking judgement. They summarise what the numbers say today.
Price History (6M)

AI Investment Committee

Committee Consensus As of September 21, 2026
Overall Committee Score
52/100
Agreement
50%
Analysts
6
Conviction
Contested
Sector Rank
Top 84%
of 192 Healthcare peers
Value Analyst neutral
55 / 100 · Moderate confidence
Fair value -- neither a bargain nor obviously overpriced
+ ROE of 29.9% shows genuine earnings power backing the valuation
− Price-to-book of 5.5x prices in significant intangible value
Growth Analyst neutral
48 / 100 · High confidence
Moderate growth -- present but not remarkable
+ Quarter-over-quarter growth rate is ACCELERATING, not just positive
− EPS declining -3.5% YoY despite any revenue growth
Technical Analyst neutral
48 / 100 · High confidence
Mixed or range-bound price action
− MACD histogram negative -- bearish momentum
Risk Analyst bearish
35 / 100 · Low confidence
Elevated risk from leverage, volatility, event exposure, or portfolio concentration -- size accordingly
− Bollinger bandwidth of 27.9% signals elevated volatility
Macro Analyst bullish
65 / 100 · Low confidence
Macro backdrop is supportive of risk assets generally, and this name's beta works in its favor
News Analyst bullish
62 / 100 · Low confidence
News flow and recent filings/analyst actions are net positive
Portfolio Manager neutral
45 / 100 · High confidence
Portfolio-level factors are mixed -- worth a deliberate sizing decision, not a default-size position
+ Portfolio position concentration is currently healthy
− Sector concentration is already high (HHI 2518.64)
Open Full Terminal →

Investment Thesis Evolution

Committee score moved marginally from 52.2 to 52.2.

Comparing 2026-09-20 to 2026-09-21 (1 day apart).

Technical Analysis

RSI (14)
36.2
Neutral
MACD Histogram
-1.172
Bearish Momentum
Trend Direction
Sideways
Weekly: Uptrend
Market Structure
Mixed
Support
$121.78
Resistance
$156.27
Bollinger %B
0.28
Inside Bands
Price vs Moving Averages
EMA 9
$141.89 Below
EMA 21
$146.71 Below
EMA 50
$150.41 Below
EMA 200
$147.17 Below

Fundamental Analysis

Valuation
67
Growth
70
Profitability
100
Financial Health
36
Cash Flow
70
Valuation
P/E Ratio 21.2×
P/B Ratio 6.40×
PEG Ratio -4.73
Dividend Yield 3.21%
52W High $170.46
52W Low $121.57
Quality & Growth
ROE 3046.9%
ROA 1216.2%
Gross Margin 7428.8%
Operating Margin 2986.1%
Revenue Growth YoY
Debt / Equity 1.18
AI Fundamental Assessment
P/E ratio of 21.2 (inexpensive relative to a 15-40x range); Price-to-book of 6.4x; PEG ratio of -4.7 (under 1.0 suggests growth is undervalued relative to price); Return on equity of 30.5%; Return on assets of 12.2%; Net margin of 23.1%; Gross margin of 74.3%; Current ratio of 0.86 (tight short-term liquidity); Debt-to-equity of 1.18; Free cash flow per share is positive (8.38); Most recent quarter beat estimates by 4.2%; EPS growth accelerating (-2.0% -> +21.1% QoQ); Analyst estimates rising over recent quarters
Get the Full NVS Analysis
Interactive charts · Live committee votes · Trade plan · Paper trading · AI Q&A
Open in Terminal →
Weekly Intelligence Brief
Get the committee's top-scored stocks every Sunday.
Free · No spam · Unsubscribe anytime